Establishment of cell lines from tumor samples and abdominal fluids of ovarian carcinoma patients
Main Article Content
Abstract
An experimental study on 50 samples from tumor and abdominal fluid of ovarian carcinoma patients was performed at K - Tan Trieu Hospital and 103 Military Hospital from December 2019 to March 2021. The purpose of this study is to establish and proliferate human cancer cell lines. Results: 100% of the samples adhered to the bottom, 28% of which had tumor cells growing with high cell density reaching over 80% of the culture plate area. The average time of first cell separation was 11.46 ± 8.07 days and the average number of separations was 2 ± 1.5. After the growth cycle, 16% of all samples were well-developed and all of them were of high-grade serous type. Tumor cells death are triggered when patient samples containing scarce tumor cells (44.7%), self-regressing tumor cells (26.1%) and bacterial or fungal infection (21.1%). The average percentage of tumor cell lines with CD46 expression was 72.65%. Conclusion: The study successfully established and proliferated tumor cell lines from patients diagnosed with ovarian carcinoma, and compared with other types, the cell lines from high-grade serous ovarian carcinoma had the most potential proliferation.
Article Details
Keywords
Establishment a cell line, ovarian carcinoma
References
2. Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA: a cancer journal for clinicians. 2018;68(4):284-296.
3. Stewart C, Ralyea C, Lockwood S. Ovarian Cancer: An Integrated Review. Seminars in oncology nursing. Apr 2019;35(2):151-156.
4. Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. The oncologist. 2002;7 Suppl 5:20-28.
5. Sueblinvong T, Ghebre R, Iizuka Y, et al. Establishment, characterization and downstream application of primary ovarian cancer cells derived from solid tumors. PLoS One. 2012;7(11):e50519.
6. Kurman RJ. WHO Classification of Tumours of Female Reproductive Organs, 4th Edition. Lyon, France: IARC. 2014.
7. Yamada T, Hattori K, Satomi H, Okazaki T, Mori H, Hirose Y. Establishment and characterization of a cell line (HCH-1) originating from a human clear cell carcinoma of the ovary. Journal of ovarian research. Jun 4 2016;9(1):32.
8. Yamada T, Kanda T, Mori H, Shimokawa K, Kagawa M, Shibayama Y. Establishment and characterization of a cell line (NOMH-1) originating from a human endometrioid adenocarcinoma of the ovary. Journal of ovarian research. Feb 4 2013;6(1):8.
9. Yamada T, Ueda M, Otsuki Y, Ueki M, Sugimoto O. Establishment and characterization of a cell line (OMC-3) originating from a human mucinous cystadenocarcinoma of the ovary. Gynecologic oncology. Feb 1991;40(2):118-128.
10. Ouellet V, Zietarska M, Portelance L, et al. Characterization of three new serous epithelial ovarian cancer cell lines. BMC Cancer. May 28 2008;8:152.
11. Howitt BE, Lee KR, Muto MG, Nucci MR, Crum CP. Chapter 25 - The Pathology of Pelvic-Ovarian Epithelial (Epithelial-Stromal) Tumors. In: Crum CP, Nucci MR, Howitt BE, Granter SR, Parast MM, Boyd TK, eds. Diagnostic Gynecologic and Obstetric Pathology (Third Edition). Philadelphia: Elsevier; 2018:865-948.
12. Hamilton TC, Young RC, McKoy WM, et al. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer research. Nov 1983;43(11):5379-5389.
13. Surowiak P, Materna V, Maciejczyk A, et al. CD46 expression is indicative of shorter revival-free survival for ovarian cancer patients. Anticancer research. 2006;26(6C):4943-4948.